[Antimalarial drug retinopathy]

Rev Med Interne. 2018 May;39(5):364-368. doi: 10.1016/j.revmed.2018.02.013. Epub 2018 Feb 26.
[Article in French]

Abstract

Introduction: Antimalarial drugs are largely used for the treatment of various systemic diseases. They can cause toxic retinopathy, which can lead to blindness.

Observation: We report the case of a 32-year-old male with a systemic lupus erythematosus treated with hydroxychloroquine 400mg per day and then chloroquine 300mg per day during 8 and 9years respectively. Eighteen months after his latest visual examination, the patient experienced bilateral vision loss. Fundus examination revealed a bull's eye maculopathy. Additional tests including multifocal electroretinogram showed severe bilateral functional impairment in the parafoveal area leading to diagnosis of severe toxic retinopathy induced by antimalarial drugs.

Discussion: In 2016, the American Academy of Ophthalmology revised the previous 2011 recommendations concerning early retinal toxicity screening strategy which should be first based on both automated 10-2 visual fields and spectral-domain optical coherence tomography (SD OCT). Multifocal electroretinogram can be more helpful for diagnostic confirmation rather than screening. Although these recommendations are essential, they are not well known in clinical practice.

Keywords: Antimalarial drug; Antipaludéens de synthèse; Electroretinogram; Lupus érythémateux systémique; Retinopathy; Rétinopathie toxique; Systemic lupus erythematosus; Électrorétinogramme.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antimalarials / adverse effects*
  • Chloroquine / adverse effects*
  • Electroretinography
  • Humans
  • Hydroxychloroquine / adverse effects*
  • Lupus Erythematosus, Systemic / drug therapy
  • Male
  • Retinal Diseases / chemically induced*
  • Tomography, Optical Coherence
  • Vision Disorders / chemically induced*

Substances

  • Antimalarials
  • Hydroxychloroquine
  • Chloroquine